Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Defronzo

Showing results (41-50 of 313) with videos related to

Pageof 32
Sort By:
Nature Reviews. Nephrology|February 6, 2021
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitorsRalph A DeFronzo, W Brian Reeves, Alaa S Awad
The Journal of Clinical Endocrinology and Metabolism|February 1, 2021
Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell FunctionXi Chen, Enrique Maldonado, Ralph A DeFronzo, et al.
Endocrine Reviews|May 25, 2011
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetesMuhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo
World Journal of Diabetes|October 15, 2015
Treatment of prediabetesMustafa Kanat, Ralph A DeFronzo, Muhammad A Abdul-Ghani
American Journal of Physiology. Renal Physiology|September 11, 2015
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusMuhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzo
Diabetes|September 26, 2013
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansMuhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton
European Heart Journal|April 1, 2008
PROactive: time for a critical appraisalD John Betteridge, Ralph A DeFronzo, Robert J Chilton
Metabolism: Clinical and Experimental|February 6, 2023
Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humansXi Chen, Aurora Merovci, Ralph A DeFronzo, et al.
Current Cardiology Reports|April 18, 2024
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?Sivaram Neppala, Jemema Rajan, Eric Yang, et al.
Diabetes Care|April 29, 2006
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucoseMuhammad A Abdul-Ghani, Devjit Tripathy, Ralph A DeFronzo
Pageof 32

Showing results (41-50 of 313) with videos related to

Sort By:
Pageof 32
Nature Reviews. Nephrology|February 6, 2021
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitorsRalph A DeFronzo, W Brian Reeves, Alaa S Awad
The Journal of Clinical Endocrinology and Metabolism|February 1, 2021
Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell FunctionXi Chen, Enrique Maldonado, Ralph A DeFronzo, et al.
Endocrine Reviews|May 25, 2011
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetesMuhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo
World Journal of Diabetes|October 15, 2015
Treatment of prediabetesMustafa Kanat, Ralph A DeFronzo, Muhammad A Abdul-Ghani
American Journal of Physiology. Renal Physiology|September 11, 2015
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusMuhammad A Abdul-Ghani, Luke Norton, Ralph A DeFronzo
Diabetes|September 26, 2013
Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansMuhammad A Abdul-Ghani, Ralph A DeFronzo, Luke Norton
European Heart Journal|April 1, 2008
PROactive: time for a critical appraisalD John Betteridge, Ralph A DeFronzo, Robert J Chilton
Metabolism: Clinical and Experimental|February 6, 2023
Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humansXi Chen, Aurora Merovci, Ralph A DeFronzo, et al.
Current Cardiology Reports|April 18, 2024
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?Sivaram Neppala, Jemema Rajan, Eric Yang, et al.
Diabetes Care|April 29, 2006
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucoseMuhammad A Abdul-Ghani, Devjit Tripathy, Ralph A DeFronzo
Pageof 32